文献速递艾滋病与性传播感染病毒性肝炎

HIV合并慢性HBV感染者启动HBV活性ART后HBsAg清除的动力学与预测因素

Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection.
PubMed 文献 · Clin Infect Dis · 2026-01-01

在泰国和马来西亚前瞻性招募97例启动HBV活性ART的HIV-HBV共感染者并随访24个月。随访期间22%个体发生HBsAg清除(11.7/100人年),多数在12个月内;基线ALT较高、含TAF方案、较年轻、肝硬度较低及qHBsAg<log10 2.0 IU/mL与HBsAg清除相关,多变量分析均显著。

要点

  • HIV-HBV共感染者启动HBV活性ART后HBsAg清除率为22%(11.7/100人年)。
  • 基线HBeAg阳性者中36.1%发生HBeAg清除,其中15例出现抗-HBe。
  • 含TAF方案、较高ALT、较年轻、较低肝硬度及qHBsAg<log10 2.0 IU/mL与HBsAg清除独立相关。

核心结论

  • HIV-HBV共感染者在启动ART后早期出现较高的HBsAg清除率。
  • 研究提示含TAF的ART方案可能作为HIV-HBV共感染的一线治疗优选。

研究设计与样本

  • 前瞻性队列研究,在泰国(n=94)和马来西亚(n=3)共招募97例启动HBV活性ART的HIV-HBV共感染者,随访24个月。
  • 采用Mann-Whitney或卡方检验进行单因素分析,Cox回归进行多变量分析。

主要发现

  • 基线HBeAg阳性者61例中22例(36.1%)发生HBeAg清除,其中15例出现抗-HBe。
  • 81%的HBsAg清除和63.6%的HBeAg清除发生在第12个月访视前,HBsAg和HBeAg清除的中位时间分别为5.8个月和12.0个月。
  • 单因素分析显示与HBsAg清除相关的基线特征包括:较高ALT(P = .005)、含TAF的ART方案(P = .025)、较年轻年龄(P = .040)、较低肝硬度(P = .010)及qHBsAg < log10 2.0 IU/mL(P = .001)。
  • 校正基线CD4计数后,上述5个因素在Cox回归分析中均保持显著。

临床怎么用

  • 在HIV-HBV共感染者启动ART时,可关注基线ALT、年龄、肝硬度、qHBsAg水平及ART方案组成,这些因素与HBsAg清除相关。
  • 研究提示含TAF的ART方案可能作为HIV-HBV共感染的一线治疗优选。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An effective therapeutic strategy for hepatis B virus (HBV) cure remains an urgent unmet need. We aimed to define the incidence, kinetics, and predictors of hepatitis B surface antigen (HBsAg) loss in people with HIV and HBV (PWH-HBV) following HBV-active antiretroviral therapy (ART) in PWH-HBV in Asia. METHODS: 97 PWH-HBV commencing HBV-active ART were recruited prospectively in Thailand (n = 94) and Malaysia (n = 3), then followed for 24 months. Time to HBV serology change was calculated. Univariate associations between baseline characteristics and HBsAg loss were examined using the Mann-Whitney or chi-square tests. Multivariable analysis was undertaken using Cox regression. RESULTS: Twenty-one individuals (22%) lost HBsAg during follow-up (11.7 per 100 person-years), 14 of whom gained anti-HBs. Twenty-two of 61 (36.1%) individuals who were hepatitis B "e" antigen (HBeAg) positive at baseline lost HBeAg over the study, 15 of whom gained anti-HBe. Most individuals lost HBsAg and HBeAg by the month 12 study visit (81% and 63.6%, respectively), with median times of 5.8 and 12.0 months to HBsAg and HBeAg loss, respectively. Univariate analysis showed baseline characteristics associated with HBsAg loss were higher alanine aminotransferase (ALT; P = .005), tenofovir alafenamide (TAF)-containing ART regimen (P = .025), younger age (P = .040), lower liver stiffness (P = .010), and quantitative HBsAg < log10 2.0 IU/mL (P = .001). All 5 factors remained significant in a Cox regression analysis that adjusted for baseline CD4 count. CONCLUSIONS: High HBsAg loss rates occur in PWH and HBV early after commencing ART. Our study suggests that TAF-containing ART regimens may be preferable as first-line therapy in HIV-HBV coinfection.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Audsley J, Avihingsanon A, Li X, et al. Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection. Clin Infect Dis. 2026. PMID: 40447285. doi:10.1093/cid/ciaf281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。